Summary of Study ST002099
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001330. The data can be accessed directly via it's Project DOI: 10.21228/M8ST3F This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002099 |
| Study Title | Functional metabolomics-based molecular profiling of acute and chronic hepatitis (Stool Metabolomics) |
| Study Summary | Non-alcoholic steatohepatitis (NASH) is a metabolic dysregulation triggered by an overload disrupting the hepatic tolerance to external molecules. With the complexity and diversity of hepatitis triggers, no effective clinical classification and treatment are available, and even using the same strategies or approaches for acute and chronic hepatitis. For us, it is really difficult to precisely diagnose and treat hepatitis accordingly. To overcome this challenge, we integrated metabolomic, lipidomics, transcriptomics and other life science frontier technologies for functional metabolomics studies, and pioneered the redefinition of hepatitis at the molecular level. Our findings suggested that acute hepatitis mainly interferes with purine metabolism and amino acids metabolism, while chronic hepatitis mainly causes disruption of hepatic bile acids and lipidome, especially glycerolipids. Based on the liver-gut axis, we also found that the metabolic regulation of the gut microbiota is another key factor for chronic hepatitis development. In conclusion, functional metabolomics enables the cognition of disease occurrence, development and regression from small molecule metabolic modifications and modulations, realizing the ultimate goal of treating diseases and improving population health through regulation of dysregulated metabolism |
| Institute | Shanghai Center for Systems Biomedicine, Shanghai Jiaotong University |
| Department | Shanghai Center for Systems Biomedicine |
| Laboratory | Lu Group |
| Last Name | Lu |
| First Name | Haitao |
| Address | 800 Dongchuan RD. Minhang District, Shanghai, Shanghai, 200240, China |
| haitao_lu@sjtu.edu.cn | |
| Phone | 15221478139 |
| Submit Date | 2022-03-09 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-03-25 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001330 |
| Project DOI: | doi: 10.21228/M8ST3F |
| Project Title: | Functional metabolomics-based molecular profiling of acute and chronic hepatitis |
| Project Type: | Targeted MS quantitative analysis |
| Project Summary: | Characteristics of liver metabolomics in acute and chronic hepatitis |
| Institute: | Shanghai Center for Systems Biomedicine, Shanghai Jiaotong University |
| Department: | Shanghai Center for Systems Biomedicine |
| Laboratory: | Lu Group |
| Last Name: | Lu |
| First Name: | Haitao |
| Address: | 800 Dongchuan RD. Minhang District, Shanghai, Shanghai, 200240, China |
| Email: | haitao_lu@sjtu.edu.cn |
| Phone: | 15221478139 |
Subject:
| Subject ID: | SU002184 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment |
|---|---|---|
| SA201288 | 20210510-C-2 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201289 | 20210510-C-7 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201290 | 20210510-C-8 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201291 | 20210510-C-6 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201292 | 20210510-C-3 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201293 | 20210510-C-4 | 3 times per week with 4 consecutive respectively intraperitoneal injection (10 mL/kg of olive oil) |
| SA201300 | 20210510-CH-5 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201301 | 20210510-CH-1 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201302 | 20210510-CH-6 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201303 | 20210510-CH-2 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201304 | 20210510-CH-7 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201305 | 20210510-CH-8 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 10% CCl4 (10 mL/kg of olive oil) |
| SA201294 | 20210510-CL-2 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201295 | 20210510-CL-3 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201296 | 20210510-CL-7 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201297 | 20210510-CL-6 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201298 | 20210510-CL-4 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201299 | 20210510-CL-1 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 1% CCl4 (10 mL/kg of olive oil) |
| SA201306 | 20210510-CM-3 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201307 | 20210510-CM-4 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201308 | 20210510-CM-8 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201309 | 20210510-CM-2 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201310 | 20210510-CM-5 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201311 | 20210510-CM-1 | 3 times per week with 4 consecutive respectively intraperitoneal injection with 5% CCl4 (10 mL/kg of olive oil) |
| SA201312 | 20210510-AL-7 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201313 | 20210510-AL-2 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201314 | 20210510-AL-5 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201315 | 20210510-AL-8 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201316 | 20210510-AL-4 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201317 | 20210510-AL-3 | Only intraperitoneally (i.p) injected with 1% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201318 | 20210510-AH-4 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201319 | 20210510-AH-3 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201320 | 20210510-AH-6 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201321 | 20210510-AH-2 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201322 | 20210510-AH-1 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| SA201323 | 20210510-AH-5 | Only intraperitoneally (i.p) injected with 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. |
| Showing results 1 to 36 of 36 |
Collection:
| Collection ID: | CO002177 |
| Collection Summary: | Animals were killed at 24h post the last CCl4 treatment and the feces samples were harvested for further assays. |
| Sample Type: | Feces |
Treatment:
| Treatment ID: | TR002196 |
| Treatment Summary: | Prior to experimental, animals were acclimatized breeding to laboratory conditions for 1 week. The mice were randomly allocated into 6 groups (n=8 each), as follows: a control group (C); two acute hepatitis groups, low and high concentrations (AL/ AH); three chronic hepatitis groups, low, middle and high concentration (CL/ CM/ CH). Mice in chronic groups were treated 3 times per week with 4 consecutive respectively intraperitoneal (i.p) injection with 1% / 5% / 10% CCl4 (10 mL/kg, dissolved in olive oil). However, in the acute groups, mice were only intraperitoneally (i.p) injected with 1% / 5% CCl4 (10 mL/kg, dissolved in olive oil) at the 12th injection. During the previous 11 times they were treated the same as the healthy controls with an equal volume of olive oil. Animals were killed at 24h post the last CCl4 treatment and serum, stool and liver tissue samples were harvested for further assays. |
Sample Preparation:
| Sampleprep ID: | SP002190 |
| Sampleprep Summary: | Stool samples with NaN3 were weighed, and 16 μL of iced methanol was added, which contains internal standard 50 mg/mL. The supernatants of the aqueous and alcoholic extracts were combined, filtered through a 0.22 µm organic phase membrane. Then transferred into the LC-TQ/MS-based metabolomic assay. |
Combined analysis:
| Analysis ID | AN003430 | AN003431 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | Reversed phase | Reversed phase |
| Chromatography system | Agilent 1290 Infinity | Agilent 1290 Infinity |
| Column | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um) | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um) |
| MS Type | ESI | ESI |
| MS instrument type | Triple quadrupole | Triple quadrupole |
| MS instrument name | Agilent 6495 QQQ | Agilent 6495 QQQ |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | counts | counts |
Chromatography:
| Chromatography ID: | CH002536 |
| Chromatography Summary: | In this study, a newly developed precision-targeted metabolomics method with a UPLC-TQ/MS system (Agilent 1290 Infnity, Agilent Technologies, USA; Agilent 6495 QQQ, Agilent Technologies, USA) in a DMRM scan-mode was applied to analyze the metabolome of interest from trial samples (serum, liver tissues and stool). Briefly, the method was performed with an ACQUITY UPLC HSS T3 column (2.1 mm i.d. × 100 mm, 1.8 μm; Waters); mobile phase A and B were water and acetonitrile with 0.1% formic acid (v/v) respectively. The flow rate was at 0.3 mL/min and the column temperature was maintained at 40 ℃. The samples were placed in an auto-sampler maintained at 4 °C with a 5 μL injection volume. The optimized gradient-elution program, as follows: 0-2 min, 98% A; 2-10 min, 98-65% A; 10-12 min, 65-20% A; 12-14 min, 20-2% A; 14-30 min, 2% A. |
| Instrument Name: | Agilent 1290 Infinity |
| Column Name: | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um) |
| Column Temperature: | 40 |
| Flow Gradient: | 0-2 min, 98% A; 2-10 min, 98-65% A; 10-12 min, 65-20% A; 12-14 min, 20-2% A; 14-30 min, 2% A |
| Flow Rate: | 0.3 mL/min |
| Solvent A: | 100% water; 0.1% formic acid |
| Solvent B: | 100% acetonitrile; 0.1% formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS003193 |
| Analysis ID: | AN003430 |
| Instrument Name: | Agilent 6495 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Agilent MassHunter Workstation Data Acquisition Agilent MassHunter |
| Ion Mode: | POSITIVE |
| MS ID: | MS003194 |
| Analysis ID: | AN003431 |
| Instrument Name: | Agilent 6495 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Agilent MassHunter Workstation Data Acquisition Agilent MassHunter |
| Ion Mode: | NEGATIVE |
